ETF Managers Group, LLC 89bio, Inc. Transaction History

ETF Managers Group, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$17.42 - $28.0 $495,895 - $797,076	-28,467 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$20.22 - $26.73 $102,798 - $135,895	5,084 Added 21.74%	28,467 $675,000
Q4 2020 Feb 16, 2021	BUY	$23.16 - $28.08 $152,323 - $184,682	6,577 Added 39.13%	23,383 $598,000
Q3 2020 Nov 16, 2020	BUY	$24.34 - $38.82 $31,788 - $50,698	1,306 Added 8.43%	16,806 $419,000
Q2 2020 Aug 14, 2020	BUY	$19.93 - $31.2 $308,915 - $483,600	15,500 New	15,500 $310,000

163

108M

73.6K

1.19M

Ticker ETNB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,484,500
Market Cap $417M
Description
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...

Get notified when there are updates to the investment portfolio of ETF Managers Group, LLC, based on Form 13F filings with the SEC.

Stay updated on ETF Managers Group, LLC with notifications on news.